The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter Hammel Pascal
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors H. Pascal1, L. Jill2, P. Fabienne3, S. Alberto4, G. Beatriz5, K. Edward6, R. Fernando7, M.J. Luis8, T. Eric9, B. Venu10, D. Scot11, A. Jamil12, S.L. Jack13, N. Thomas13, K. Louis13, P. Philip14
  • 1Service de Gastroentérologie, Hôpital Beaujon, Clichy, France, /
  • 2Yale Cancer Center, New Haven, Connecticut, USA, /
  • 3Institut Régional du Cancer, Montpellier, France, /
  • 4IRCCS Ospedale San Martino IST, Genova, Italy, /
  • 5Hospital Clínico San Carlos Madrid, Madrid, Spain, /
  • 6UC Davis Medical Center, Sacramento, California, USA, /
  • 7Hospital Universitario Marqués de Valdecilla, Santander, Spain, /
  • 8H. Germans Trias i Pujol, Badalona, Spain, /
  • 9Service d' Hépato-Gastroentérologie et d'Oncologie Digestive du Groupe Hospitalier Sud, Hôpital Haut Lévèque, Centre Hospitalier Universitaire, Pessac, France, /
  • 10Cancer Center of Excellence, University of Massachusetts Medical School, Worcester, Massachusetts, USA, /
  • 11Tom Baker Cancer Centre, Calgary, Canada, /
  • 12McGill University Royal Institution, Montreal, Canada, /
  • 13Celgene Corporation, Summit, New Jersey, USA, /
  • 14Karmanos Cancer Center, Detroit, Michigan, USA, /


Efficacious systemic therapies for LAPC may be associated with improved local disease control and overall survival (OS). The phase 3 MPACT trial in patients with previously untreated metastatic PC demonstrated longer OS (median, 8.7 vs 6.6 months; hazard ratio 0.72; P < 0.001) and an ≈ 3-fold greater shrinkage of primary pancreatic tumors with nab-P + Gem vs Gem alone (−22.15% vs −7.02%), which suggests the potential for improved local PC control with this combination. The LAPACT trial will evaluate efficacy and safety of nab-P + Gem in treating patients with LAPC.